File:Ondansetron_structure.svg · Wikimedia Commons · See Wikimedia Commons
اندانسترون
Sign in to saveAlso known as ODT032, GR-38032F/GR-38032
Ondansetron, sold under the brand name Zofran among others, is a medication used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, migraines, or surgery. It is also effective for treating gastroenteritis. It can be given orally (by mouth), intramuscularly (injection into a muscle), or intravenously (injection into a vein).
OverviewAI-generated
Ondansetron is a chemical compound with the formula C₁₈H₁₉N₃O. Its IUPAC name is 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one. The substance has a molecular weight of 293.4 and a mass of 293.152812. It possesses a defined daily dose of 16.
Chemical properties include an xlogp value of 2.3 and a topological polar surface area of 39.8. The molecule contains zero hydrogen bond donors and two hydrogen bond acceptors, with a charge of 0. It is referenced by 1,716 other encyclopedia articles.
Synthesized by Vinony from 18 facts across 4 sources: Wikidata, PubMed, PubChem, Vinony graph. Generated from structured data (not the Wikipedia text) and checked against those facts — may still contain errors.
Key facts
- Drug.ChEMBL
- 46
- Drug.verifiedrevid
- 477170896
- Drug.image
- Ondansetron skeletal.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 225
- Drug.image2
- Ondansetron 3D.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 250
- Drug.tradename
- Zofran, others
- Drug.MedlinePlus
- a601209
- Drug.DailyMedID
- Ondansetron
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- By mouth, rectal, intravenous, intramuscular, thin film
- Drug.ATC_prefix
- A04
- Drug.ATC_suffix
- AA01
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
via Wikipedia infobox
Chemical data
- Formula
- C18H19N3O
- Molecular weight
- 293.4 g/mol
- IUPAC name
- 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
- SMILES
- CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
- InChIKey
- FELGMEQIXOGIFQ-UHFFFAOYSA-N
- XLogP
- 2.3
- Polar surface area
- 39.8 Ų
- H-bond donors
- 0
- H-bond acceptors
- 2
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1991
- Admin. routes
- oral, parenteral
- Indications
- Fish-eye disease, Nausea, obsessive-compulsive disorder, post operative nausea and vomiting
via ChEMBL · EBI
Research
5,903 papers- Ondansetron.European journal of cancer (Oxford, England : 1990) · 1993
- Ondansetron.Indian pediatrics · 1995
- Ondansetron clinical pharmacokinetics.Clinical pharmacokinetics · 1995
- Ondansetron for Shivering after Spinal Anesthesia in Cesarean Delivery: A Systematic Review and Meta-analysis.Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses · 2022
- Ondansetron reduces the incidence of hypotension after spinal anaesthesia in non-caesarean delivery: A systematic review and meta-analysis.Journal of perioperative practice · 2022
via PubMed
Wikidata facts
Show 8 more facts
- significant drug interaction
- apomorphine
- chemical formula
- C₁₈H₁₉N₃O
- Commons category
- Ondansetron
- World Health Organisation international non-proprietary name
- ondansetron
- medical condition treated
- gastroenteritis
- canonical SMILES
- CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
- subject has role
- antipruritic
- defined daily dose
- 16
Sources (6)
via Wikidata · CC0